From Blockbuster Injections to a Pill-Driven Mass Market
The injectable GLP-1 market was already extraordinary by any benchmark. J.P. Morgan Global Research projects the global incretin market — which includes GLP-1 drugs — will reach $200 billion by 2030, with approximately 25 million Americans on treatment by that year, up from roughly 10 million in 2025. But the drugs' reliance on injectable formats created a natural ceiling. A meaningful segment of patients simply won't self-inject, regardless of clinical benefit. Goldman Sachs analysts forecast that oral GLP-1s could capture around 24% of the global weight-loss drug market by 2030 — roughly $22 billion — precisely because they unlock that untapped patient population.
The shift isn't just about patient convenience. It changes the competitive economics entirely. Manufacturing an oral pill at scale is a different supply chain challenge than producing peptide-based injectables, which require cold chain logistics and complex biologics manufacturing. Novo Nordisk and Eli Lilly spent years navigating injectable supply shortages as demand outpaced production capacity. Pills introduce new formulation chemistry challenges — oral bioavailability for peptide drugs is notoriously difficult — but eliminate cold chain dependencies and reduce per-dose manufacturing complexity at volume. Whichever company cracks cost-effective mass-market oral production first gains a structural advantage that isn't easily replicated.
What the Market Transition Means for Adjacent Industries
The GLP-1 boom has already disrupted sectors far beyond pharma. Food and beverage companies have been recalibrating product portfolios as GLP-1 users report reduced appetite and shifting food preferences. Bariatric surgery volumes are under pressure. Medical device makers in diabetes management are watching their addressable markets evolve. Oral GLP-1s accelerate all of these effects by removing the injection barrier and expanding the patient population significantly — J.P. Morgan estimates 30 million U.S. users by 2030 under scenarios that include widespread oral availability. The downstream demand signal for high-protein, lower-calorie food formats, GLP-1 companion diagnostic tools, and adherence support platforms is strengthening accordingly.
The competitive dynamic between Novo Nordisk and Eli Lilly is also entering a new phase. Both companies are explicit that the next battleground is personalized obesity medicine — different drugs for different patient metabolic profiles — rather than a single dominant molecule. Eli Lilly's chief scientific officer told CNBC in January 2026 that the market is moving from a "one-size-fits-all" model toward differentiated options. That shift will benefit companies with deep pharmacogenomics capabilities and real-world evidence platforms that can match patients to therapies. For investors, the key variable isn't which oral GLP-1 wins the initial approval race — it's which company builds the data infrastructure to dominate precision obesity care through the end of the decade.